Mohamed Abou-El-Enein
Cited by
Cited by
Overcoming challenges facing advanced therapies in the EU market
M Abou-El-Enein, A Elsanhoury, P Reinke
Cell Stem Cell 19 (3), 293-297, 2016
Good Manufacturing Practices (GMP) manufacturing of advanced therapy medicinal products: a novel tailored model for optimizing performance and estimating costs
M Abou-El-Enein, A Römhild, D Kaiser, C Beier, G Bauer, HD Volk, ...
Cytotherapy 15 (3), 362-383, 2013
Concise Review: A comprehensive analysis of reported adverse events in patients receiving unproven stem cell‐based interventions
G Bauer, M Elsallab, M Abou‐El‐Enein
Stem cells translational medicine 7 (9), 676-685, 2018
A roadmap toward clinical translation of genetically-modified stem cells for treatment of HIV
M Abou-El-Enein, G Bauer, P Reinke, M Renner, CK Schneider
Trends in molecular medicine 20 (11), 632-642, 2014
Putting a price tag on novel autologous cellular therapies
M Abou-El-Enein, G Bauer, N Medcalf, HD Volk, P Reinke
Cytotherapy 18 (8), 1056-1061, 2016
Strategies for derisking translational processes for biomedical technologies
M Abou-El-Enein, GN Duda, EA Gruskin, DW Grainger
Trends in biotechnology 35 (2), 100-108, 2017
The business case for cell and gene therapies
M Abou-El-Enein, G Bauer, P Reinke
Nature biotechnology 32 (12), 1192-1193, 2014
Human genome editing in the clinic: new challenges in regulatory benefit-risk assessment
M Abou-El-Enein, T Cathomen, Z Ivics, CH June, M Renner, ...
Cell Stem Cell 21 (4), 427-430, 2017
Enhancing patient-level clinical data access to promote evidence-based practice and incentivize therapeutic innovation
A Fortunato, DW Grainger, M Abou-El-Enein
Advanced drug delivery reviews 136, 97-104, 2018
Deciphering the EU clinical trials regulation
M Abou-El-Enein, CK Schneider
Nature biotechnology 34 (3), 231-233, 2016
Accelerating patients’ access to advanced therapies in the EU
A Elsanhoury, R Sanzenbacher, P Reinke, M Abou-El-Enein
Molecular Therapy-Methods & Clinical Development 7, 15-19, 2017
Clinical development of cell therapies: setting the stage for academic success
M Abou‐El‐Enein, HD Volk, P Reinke
Clinical Pharmacology & Therapeutics 101 (1), 35-38, 2017
The human genome editing race: loosening regulatory standards for commercial advantage?
T Cathomen, S Schüle, M Schüßler-Lenz, M Abou-El-Enein
Trends in biotechnology 37 (2), 120-123, 2019
Telbivudine in chronic lymphocytic myocarditis and human parvovirus B19 transcriptional activity
S Van Linthout, A Elsanhoury, O Klein, M Sosnowski, K Miteva, D Lassner, ...
ESC heart failure 5 (5), 818-829, 2018
Registry contributions to strengthen cell and gene therapeutic evidence
M Abou-El-Enein, DW Grainger, S Kili
Molecular Therapy 26 (5), 1172-1176, 2018
The path to successful commercialization of cell and gene therapies: empowering patient advocates
G Bauer, M Abou-El-Enein, A Kent, B Poole, M Forte
Cytotherapy 19 (2), 293-298, 2017
Cell and gene therapy trials: are we facing an ‘evidence crisis’?
M Abou-El-Enein, SP Hey
EClinicalMedicine 7, 13-14, 2019
Gene therapy: a possible future standard for HIV care
M Abou-El-Enein, G Bauer, P Reinke
Trends in biotechnology 33 (7), 374-376, 2015
CAR T-cell product performance in haematological malignancies before and after marketing authorisation
M Elsallab, BL Levine, AS Wayne, M Abou-El-Enein
The Lancet Oncology 21 (2), e104-e116, 2020
The Economics of Manufacturing Clinical-grade Advanced Therapy Medicinal Products (ATMPs)
MA El-Enein
Medizinische Fakultät Charité-Universitätsmedizin Berlin, 2014
The system can't perform the operation now. Try again later.
Articles 1–20